乌司奴单抗注射液（45mg/0.5ml/支）-STARJEMZA®USYMRO®-Bio-Thera Solutions, Ltd.

STARJEMZA / UYMRO®Ustekinumab（45 mg/0.5mL）

Please use it under the supervision of a healthcare professional.

STARJEMZA®/USYMRO® is a biosimilar to Janssen’s Stelara® which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 subunit from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of immune cells. IL-12 and IL-23 are involved in inflammatory and immune responses, such as natural killer cell activation, CD4+ T-cell differentiation and following relative cytokines stimulated release. Abnormal regulation of IL-12 and IL-23 have been implicated as important contributors to chronic inflammation, including psoriasis, psoriatic arthritis (PsA), and Crohn’s disease. Neutralizing human IL-12 and IL-23 by STARJEMZA®/USYMRO® to prevent the relevant cell signaling in the Th1 or Th17 lineages can effectively block the pathologic processes of these immune disorders.

药品说明书

STARJEMZA / UYMRO®

In the US, STARJEMZA® (ustekinumab-hmny) Injection is indicated for the treatment of severe plaque psoriasis, active psoriatic arthritis, moderate to severe active Crohn's disease, and moderate to severe active ulcerative colitis. At launch, STARJEMZA® is currently marketed in the United States in two different subcutaneous injection formulations (45mg/0.5mL and 90mg/L) and one intravenous injection formulation (130mg/26mL).

In the Europe, USYMRO® is indicated for the treatment of moderately to severe plaque psoriasis, active psoriatic arthritis, moderate to severe active Crohn's disease.

STARJEMZA / UYMRO®Ustekinumab（45 mg/0.5mL）

Please use it under the supervision of a healthcare professional.